DURECT Corporation (NASDAQ:DRRX)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a report issued on Thursday, November 2nd.
Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus upgraded shares of DURECT Corporation from a “hold” rating to a “buy” rating and lifted their target price for the stock from $1.25 to $3.00 in a research report on Wednesday, July 12th. Laidlaw decreased their price objective on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th. Finally, ValuEngine upgraded shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th.
DURECT Corporation (NASDAQ:DRRX) remained flat at $$1.09 during trading on Thursday. 1,799,506 shares of the company’s stock traded hands, compared to its average volume of 709,200. DURECT Corporation has a 12 month low of $0.74 and a 12 month high of $2.17. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46.
DURECT Corporation (NASDAQ:DRRX) last issued its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.09. The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $5.09 million. DURECT Corporation had a negative net margin of 62.57% and a negative return on equity of 419.65%. sell-side analysts expect that DURECT Corporation will post -0.14 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “DURECT Corporation (NASDAQ:DRRX) Stock Rating Reaffirmed by HC Wainwright” was first reported by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/durect-corporation-drrx-rating-reiterated-by-hc-wainwright/1750916.html.
Several institutional investors and hedge funds have recently made changes to their positions in DRRX. Ingalls & Snyder LLC boosted its stake in shares of DURECT Corporation by 213.1% during the 2nd quarter. Ingalls & Snyder LLC now owns 6,419,482 shares of the specialty pharmaceutical company’s stock valued at $10,014,000 after purchasing an additional 4,369,400 shares in the last quarter. Asymmetry Capital Management L.P. bought a new stake in DURECT Corporation during the second quarter worth about $1,636,000. Mangrove Partners boosted its stake in DURECT Corporation by 274.5% during the third quarter. Mangrove Partners now owns 1,271,591 shares of the specialty pharmaceutical company’s stock worth $2,251,000 after acquiring an additional 932,070 shares in the last quarter. Tocqueville Asset Management L.P. boosted its stake in DURECT Corporation by 70.3% during the third quarter. Tocqueville Asset Management L.P. now owns 2,043,383 shares of the specialty pharmaceutical company’s stock worth $3,617,000 after acquiring an additional 843,383 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its stake in DURECT Corporation by 13.4% during the second quarter. Stonepine Capital Management LLC now owns 3,175,994 shares of the specialty pharmaceutical company’s stock worth $4,955,000 after acquiring an additional 374,618 shares in the last quarter. 46.13% of the stock is currently owned by hedge funds and other institutional investors.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with our FREE daily email newsletter.